What are the common side effects of Retifanlimab (Zynyz)?

Retifanlimab (trade nameZynyz) is an immune checkpoint inhibitor mainly used to treat locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). As a new type of immunotherapy drug, Retifanlimab blocks PD-1 protein and restores the immune system's recognition and attack of tumor cells, thereby achieving anti-cancer effects. However, like most immunotherapy drugs, Retifanlimab may also cause a series of side effects while exerting therapeutic effects. Understanding the types, manifestations and countermeasures of these side effects is of great significance for patients to rationally use drugs and optimize treatment effects.

First of all, immune-related adverse events (immune-related adverse events, irAEs) are the most typical side effects of Retifanlimab and require special attention. This type of side effect is mainly caused by the drug lifting the immune system's suppression of its own tissues, causing immune cells to attack normal tissues and produce an inflammatory reaction. Common immune-related adverse reactions include skin reactions (such as rash, itching), enteritis (diarrhea, colitis), pneumonia (dyspnea, cough), hepatitis (jaundice, abnormal liver function), and endocrine system abnormalities (thyroid dysfunction, adrenal insufficiency). The severity of these reactions can range from mild discomfort to life-threatening, requiring doctors to closely monitor the patient's clinical manifestations and relevant laboratory indicators and adjust treatment plans in a timely manner.

Secondly, infusion-related reactions are also one of the common side effects of Retifanlimab. Patients may develop fever, chills, rash, itching, shortness of breath and even allergic reactions when receiving intravenous infusion of Retifanlimab. This type of reaction often occurs in the early stages of medication, and doctors generally take preventive measures, such as giving antihistamines, corticosteroids, or slowing down the infusion rate, to reduce the incidence of adverse reactions. Patients must cooperate closely with medical staff during the infusion process and should report any abnormal symptoms immediately.

In addition, Retifanlimab may cause other common adverse reactions including fatigue, nausea, decreased appetite, joint pain and muscle pain. Although most of these symptoms are mild, they may still affect the patient's quality of life, especially during long-term treatment. Doctors usually take symptomatic and supportive treatment based on the patient's specific situation, such as analgesia, nutritional support and psychological counseling, to help patients reduce discomfort and maintain treatment tolerance.

It is important to note that there is a risk of serious but rare side effects during Retifanlimab treatment. For example, immune-mediated neurological disorders (such as Guillain-Barré syndrome), myocarditis, or nephritis are all medical emergencies. Once corresponding symptoms appear, such as severe headache, confusion, chest pain, or significant decrease in urine output, you should seek medical attention immediately. During treatment, doctors will choose to suspend or terminate medication based on the severity of side effects, and if necessary, use immunosuppressants such as glucocorticoids to control overactive immune responses.

In summary, RetifanlimabThe common side effects mainly include immune-related adverse reactions, infusion-related reactions and some mild systemic symptoms. Paying attention to and managing these side effects will not only help improve patients' treatment tolerance, but also optimize efficacy and extend patient survival. In the future, with the accumulation of clinical experience and in-depth research, the prevention and treatment measures for the side effects of Retifanlimab will be more perfect, bringing good news to more patients.

https://www.fda.gov/drugs/resources-information-approved-drugs